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Abstract: In a previous article, we reported on the higher toxicity of silver(I) complexes of micon-
azole [Ag(MCZ)2NO3 (1)] and [Ag(MCZ)2ClO4 (2)] in HepG2 tumor cells compared to the corre-
sponding salts of silver, miconazole and cisplatin. Here, we present the synthesis of two silver(I) 
complexes of miconazole containing two new counter ions in the form of Ag(MCZ)2X (MCZ = 
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole]; X = BF4− (3), SbF6− (4)). 
The novel silver(I) complexes were characterized by elemental analysis, 1H NMR, 13C NMR and 
infrared (IR) spectroscopy, electrospray ionization (ESI)-MS spectrometry and 
X-ray-crystallography. In the present study, the antimicrobial activity of all obtained silver(I) 
complexes of miconazole against six strains of Gram-positive bacteria, five strains of 
Gram-negative bacteria and yeasts was evaluated. The results were compared with those of a silver 
sulfadiazine drug, the corresponding silver salts and the free ligand. Silver(I) complexes exhibited 
significant activity against Gram-positive bacteria, which was much better than that of silver sul-
fadiazine and silver salts. The highest antimicrobial activity was observed for the complex con-
taining the nitrate counter ion. All Ag(I) complexes of miconazole resulted in much better inhibi-
tion of yeast growth than silver sulfadiazine, silver salts and miconazole. Moreover, the synthe-
sized silver(I) complexes showed good or moderate activity against Gram-negative bacteria com-
pared to the free ligand. 
Keywords: synthesis; silver(I) complexes; NMR spectroscopy; IR spectroscopy; X-ray crystallog-
raphy; antimicrobial activity 
 
1. Introduction 
Currently, drug resistance to chemotherapeutics and antibiotics is a serious problem 
in modern medicine. Therefore, solving this problem has become a challenge for re-
searchers. Despite growing public awareness and the development of treatment meth-
ods, prolonged antibiotic therapy and medicine abuse have contributed to an increase in 
the number of deaths caused by antibiotic-resistant bacterial strains [1]. This intensifies 
the need to search for new compounds with various mechanisms of action and potential 
antimicrobial properties. A literature review clearly shows the growing interest in the 
use of precious metals in medicine as an alternative in fighting infections. The latest 
research shows that new compounds containing elements such as gold, silver, nickel or 
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ruthenium have promising potential and can be used as compounds with antimicrobial 
properties in the fight against infections [2,3]. Many researchers focus their attention on 
silver, which is used in medicine due to its strong antibacterial activity against 
Gram-positive and Gram-negative bacteria and fungi [4]. 
Silver and its compounds have been used in medicine since 4000 years B.C. [5,6]. The 
medical use of silver was documented in the literature as early as the 17th and 18th cen-
turies [7]. Due to its properties, it was used to treat burns and skin ulcers, to treat stomach 
ulcers and to sterilize medical instruments, among other purposes. Silver and its com-
pounds have also been used in the treatment of gonorrhea, tetanus and colds [8–12]. Sil-
ver nitrate solution was used during the Credé procedure to prevent gonorrhea conjunc-
tivitis in newborns [13,14]. Silver proteinate, known as protargol and argyrol, has also 
been used in neonatal ophthalmology to treat neonatal conjunctivitis. Contrary to silver 
nitrate, silver proteinate was neither corrosive nor irritating [15–17]. Another substance 
used is the complex compound silver sulfadiazine, which is formed by combining two 
antibacterial substances: the sulfonamide group (sulfadiazine) and silver ion. Silver sul-
fadiazine is used in the form of a cream (Flamazine® ) to combat fungal and bacterial in-
fections and skin burns. However, its use is associated with the occurrence of side effects, 
such as allergic reactions, gastrointestinal reactions and slow wound healing [18–22]. 
Currently, many researchers are focusing on the synthesis of silver(I) complexes due 
to the low toxicity of silver ions in humans and the improved action of such compounds 
compared to popular antibiotics. In addition, coordination of different ligands to Ag(I) 
ions can achieve the prolonged release of Ag(I) ions at the site of infection to combat 
certain infections. Silver(I) complexes have been proven to exhibit antibacterial [23–26], 
antifungal [27–30] and anticancer [31–37] properties that are better than those of the free 
ligand. 
Imidazole derivatives constitute an important class of compounds and have been 
studied for many years. Miconazole (Figure 1) was approved for use in 1971 and is in-
cluded in the list of essential drugs of the World Health Organization [38,39]. It is a drug 
with a broad spectrum of antifungal activity. It is used externally in dermatophyte and 
fungal skin infections and vaginal candidiasis [40–43]. Miconazole is also bactericidal 
against various strains of Gram-positive aerobic bacteria. It is not active against 
Gram-negative bacteria [44,45]. 
 
Figure 1. Chemical structure of miconazole. 
The antibacterial mechanism of action of silver(I) metal complexes may be different, 
which is promising for slowing down the development of drug resistance in bacteria. 
Catalytic oxidation, reactions with the cell wall of bacteria, protein denaturation and 
binding to DNA, which leads to the death of bacteria, are indicated as methods of deac-
tivation of bacteria by silver [46–49]. This provides a basis for continued research and the 
discovery of new compounds of silver(I) complexes. 
In our previous article, we described the synthesis of two new silver(I) complexes of 
miconazole, [Ag(MCZ)2NO3 (1)] and [Ag(MCZ)2ClO4 (2)], and tested their cytotoxicity 
using Balb/c 3T3 and HepG2 cell lines [50]. The obtained results were promising and 
provided a broader horizon for silver(I) complexes. 
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Therefore, we synthesized new silver(I) complexes of miconazole containing new 
counter ions (BF4− (3), SbF6− (4)), which are described in this publication. In this paper, we 
present the synthesis of the newly obtained silver(I) complexes of miconazole. The ob-
tained compounds were characterized by spectroscopic methods (1H NMR, 13C NMR, 
infrared (IR)), electrospray ionization (ESI)-MS, elemental analysis and X-ray measure-
ments. In addition, we examined the antimicrobial activity of all silver(I) complexes of 
miconazole (1–4) that we developed so far against selected Gram-positive and 
Gram-negative bacteria and yeasts by calculating the minimum inhibitory concentration 
(MIC) and minimum bactericidal concentration (MBC) values. 
2. Results and Discussion 
2.1. Synthesis of [Ag(MCZ)2NO3] (1) and [Ag(MCZ)2ClO4] (2) 
The synthesis of both complexes and their crystal structures were described in our 
previous article. Both silver(I) complexes are in monomeric forms. They consist of the 
appropriate counter ions (nitrate and perchlorate) and silver(I) ions coordinated by two 
miconazole ligands. Their spectroscopic properties (IR, 1H NMR, ESI-MS), X-ray diffrac-
tion analysis and cytotoxic potential against the HepG2 human liver cancer cell line were 
previously determined and reported [50]. 
Generally, both complexes were obtained via reaction of the corresponding silver 
salts (AgX = NO3− (1), ClO4− = (2)) with miconazole in a 1:2 molar metal-to-ligand ratio. A 
scheme for the synthesis of silver(I) complexes of miconazole is shown below (Scheme 1). 
 
Miconazole         X= NO3 (1), ClO4 (2) 
Scheme 1. Synthesis of silver(I) complexes of miconazole (1) and (2). 
2.2. Synthesis of [Ag(MCZ)2BF4] (3) and [Ag(MCZ)2SbF6] (4) 
The new silver(I) complexes of miconazole were synthesized in an easy process in a 
reaction of AgBF4 and AgSbF6 with miconazole (1:2) (Scheme 2) in water/ethanol. The 
complexes were obtained in good yield. 
 
Miconazole         X= BF4 (3), SbF6 (4) 
Scheme 2. Synthesis of silver(I) complexes of miconazole (3) and (4). 
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2.3. NMR Spectroscopy 
The characteristics of the 1H NMR spectra for [Ag(MCZ)2NO3] (1) and 
[Ag(MCZ)2ClO4] (2) complexes were described in our previous work [50]. The 1H and 13C 
NMR spectra of the newly synthesized complexes and free miconazole ligand were rec-
orded in CDCl3. Carbon and hydrogen atoms are numbered as shown in Figure 1. 
In the spectrum of miconazole, signals appear at 7.26 and 7.27 ppm, which are at-
tributed to H4 and H5 protons of the imidazole ring. The signals assigned to H3 and H3’ 
protons in the dichlorophenyl rings are observed in the spectrum of the free ligand at 7.38 
and 7.48 ppm. The spectrum of the free ligand also shows signals at 7.32 and 7.33 ppm, 
which are assigned to H6’ and H5’ protons. For H6 and H5 protons, signals are recorded 
at 7.16 and 7.20. The aliphatic CH proton is recorded at 4.10 ppm, while for two aliphatic 
protons, CH2 signals between 4.27 and 4.52 ppm are observed. The signals recorded in 
the miconazole spectrum in this study are consistent with the literature values [51].  
In the 1H NMR spectra of all silver(I) complexes of miconazole (1–4) that we ob-
tained so far, slight shifts to a higher field are observed compared to the spectra of 
miconazole (Table 1). Moreover, in the silver(I) complex spectra, signals appear at 8.08 
ppm for compound 1, at 8.20 ppm for 2, at 8.17 ppm for 3 and at 8.13 ppm for compound 
4. These signals can be assigned to the H2 proton in the imidazole ring. In the miconazole 
spectrum, this band is not recorded. A review of the literature shows that the slight shifts 
to the higher field for silver(I) complexes compared to the free ligand are not surprising. 
This indicates the effect of coordination of the ligand through the nitrogen atom of the 
imidazole ring with Ag(I) ions, only slightly reflected in the peripheral ring protons [52–
55]. Spectra of the silver(I) complexes of miconazole 3 and 4 are presented in Supple-
mentary Figure S1. 
Table 1. Proton chemical shifts in ppm for miconazole and complex compounds at room temper-


















Imidazole      
H2 - 8.08 8.20 8.17 8.13 
H4 7.26 7.32 7.33 7.33 7.33 
H5 7.27 7.34 7.34 7.34 7.34 
2,4-Dichlorophenyl      
(Ring I) H3 7.37 7.40 7.40 7.41 7.42 
(Ring I) H5 7.20 7.29 7.29 7.29 7.29 
(Ring I) H6 7.16 7.08 7.09 7.07 7.05 
(Ring II) H3′ 7.49 7.49 7.49 7.49 7.49 
(Ring II) H5′ 7.33 7.37 7.39 7.39 7.41 
(Ring II) H6′ 7.32 7.36 7.35 7.35 7.36 
Aliphatic-CH 4.10 4.16 4.19 4.20 4.20 
2-Aliphatic-CH2 4.27–4.52 4.29–4.55 4.32–4.56 4.33–4.56 4.34–4.56 
The 13C NMR spectroscopic data for 3 and 4 in comparison to the free ligand are 
presented in Table 2. The registered spectra of silver(I) complexes of miconazole and the 
free ligand are similar. In this case, slight shifts towards the higher field are also observed 
in relation to the ligand spectrum. The signals of the C2 carbons in the imidazole ring for 
compounds 3 and 4 appear at 140.40 and 140.41 ppm, respectively. In the spectrum of 
miconazole, this band appears at 138.31 ppm, which also confirms the connection of 
Ag(I) with the ligand through the nitrogen atom of the imidazole ring. 13C NMR spectra 
of 3, 4 and miconazole are presented in Supplementary Figure S2. 
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Table 2. 13C NMR spectroscopy data for silver(I) complexes and the free ligand. 








Imidazole    
C2 138.31 140.40 140.41 
C4 120.43 121.50 121.49 
C5 125.76 127.89 127.89 
(Ring I) C1 135.01 134.61 134.61 
(Ring I) C2 134.55 134.40 134.39 
(Ring I) C3 129.74 129.82 129.81 
(Ring I) C4 134.09 134.31 134.31 
(Ring I) C5 129.07 129.56 129.57 
(Ring I) C6 128.31 129.14 129.15 
(Ring II) C1′ 133.58 133.72 133.72 
(Ring II) C2′ 133.53 133.67 133.67 
(Ring II) C3′ 129.35 129.56 129.57 
(Ring II) C4′ 134.13 131.38 131.38 
(Ring II) C5′ 128.65 129.30 129.30 
(Ring II) C6′ 127.86 128.42 128.42 
C7 77.49 76.95 76.95 
C8 50.42 50.97 50.97 
C8′ 67.79 67.85 67.85 
2.4. IR Spectroscopy 
The IR spectra of complexes 1 and 2 were characterized in our recent work [50]. In 
the miconazole spectrum, a band at 3151 cm−1 is observed, which is assigned to the CN 
vibration of the imidazole group [56]. This band for complexes 3 and 4 is located at 3180 
(4) and 3182 cm−1 (3), respectively. In the free drug spectrum, a band at 3109 cm−1 corre-
sponding to aromatic CH stretching [56] is observed, and in the complex spectra, these 
vibrations appear at 3129 (3) and 3137 cm−1 (4), respectively. 
The spectrum of the free ligand has bands at 1589 and 1562 cm−1, which are at-
tributed to C—C stretching vibrations of the dichlorobenzene groups. In the spectra of 
complexes 3 and 4, these bands appear at 1590 cm−1 for 3 and 4 as well as 1561 (4) and 
1562 cm−1 (3). The bands at 1505 cm−1 in the miconazole spectrum can be attributed to 
C—C stretching vibrations of the imidazole group and CH bending of the imidazole 
group, i.e., the C6 aliphatic part of the ligand [57]. The spectrum of miconazole also 
shows a band at 1468 cm−1, which is attributed to CH bending vibrations of two dichlo-
robenzene groups. In the spectra of silver(I) complexes with miconazole, this band is lo-
cated at 1470 (4) and 1471 cm−1 (3). The band appearing in the miconazole spectrum at 
1092 cm−1, attributable to the stretching vibrations of the C—O—C group [57], is found at 
1094 (3) and 1095 cm−1 (4) in the spectrum of the complexes. The lack of significant band 
shifts originating from the C—O—C group for the silver(I) complexes indicates a lack of 
coordination by this group. In the spectra of silver(I) complexes, bands at 1728 cm−1 for 
compound 3 and 1729 cm−1 for 4 are observed. This band is not observed in the spectrum 
of the free ligand. It can be assumed that these bands are derived from the stretching vi-
brations of the C═N group of the imidazole nitrogen [50]. This indicates the connection of 
Ag(I) ions with miconazole by the nitrogen of the imidazole group. This is also confirmed 
by the X-ray structure of the obtained single crystals of silver(I) complexes 3 and 4. 
Moreover, strong bands appear in the spectra of the complexes at 1071 cm−1 for com-
pound 3 and 658 cm−1 for compound 4, which is confirmed by the presence of BF4 and 
SbF6 anions [58]. In addition, a higher intensity of the bands is indicated in the spectra of 
the complexes compared to the spectrum of the free drug. The spectra of silver(I) com-
plexes 3 and 4 are presented in Supplementary Figure S3. 
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2.5. Light Stability 
The study was carried out for complexes of silver(I) with miconazole 1–4 and for the 
corresponding silver salts used for comparison purposes. The light stability of the com-
plexes was monitored under light in an air atmosphere at room temperature to check 
their light stability under natural living conditions. Solutions of the complexes and silver 
salt at a concentration of 0.05 mol/L were applied to various substrates (paper, tissue 
paper and glass) and visually monitored for 0, 1, 4, 18, 24, 40, 48, 52, 60, 84 and 108 h. 
AgNO3, AgClO4, AgBF4 and AgSbF6 slightly darkened after 1 h of exposure to light, 
while after 40 h, their complete blackening was observed on tissue paper and paper. On 
the glass, their decomposition was a bit slower. Silver(I) complexes of miconazole 1–4 
remained unchanged on all substrates throughout the experiment. In summary, the sta-
bility of complex compounds 1–4 under light turned out to be much better than that of 
the corresponding silver salts. The silver salt decomposition proceeded rapidly, while the 
silver(I) complexes of miconazole remained unchanged (Supplementary Figure S4). 
The results of the experiment carried out are promising for the possible use of 
compounds 1–4 as antibacterial agents for external application, e.g., in the form of oint-
ments. 
2.6. X-Ray Single-Crystal Structure Determination 
The molecular structures of the new Ag(I) complexes of miconazole with two dif-
ferent counter ions, tetrafluoroborate (3) and hexafluoroantimonate (4), are displayed in 




Figure 2. Molecular structures of Ag(I) complexes of miconazole with tetrafluoroborate (3) (a) and hexafluoroantimonate 
(4) (b) counter ions. The anisotropic displacement ellipsoids are drawn at the 30% probability level. For clarity, only the 
major components of the disordered atoms (F2A, Cl2A, Cl3A, H18) are shown. Symmetry codes: 3 (i) −x, y, −z + ½ ; 4 (i) −x 
+ 1, −y + 2, −z + 1; (ii) x + 2, −y + 2, −z + 1. 
In 3, the Ag1 and B1 atoms are located on a two-fold symmetry axis, whereas in 4, 
the Ag1 and Sb1 atoms lie on inversion centers. In both cases, the silver(I) ion is linearly 
coordinated by two symmetrically related miconazole ligands, which is confirmed by 
the N-Ag-N angle of 176.5(2)° for 3 and 180° for 4. The Ag-N distances are 2.058(4)Å  and 
2.092(3) Å  for 3 and 4, respectively. The former distance is the shortest observed of the 
four complexes of silver(I) with miconazole ligands and different counter ions (1–4). 
Figure 3 presents the overlay of four independent miconazole skeletons determined 
in silver(I) complexes 1–4. As it is clearly seen, the molecular conformation of the 
miconazole ligands in complexes with perchlorate (2, green) and tetrafluoroborate (3, 
red) anions is identical. Noticeable differences are found in the orientations of the di-
chlorophenyl rings for miconazole moieties in the complexes with nitrate (1, blue) and 
hexafluoroantimonate (4, magenta) anions. Additionally, the orientation of the imidaz-
ole ring in complex 1 differs from the others. 




Figure 3. A superposition of miconazole ligands in Ag(I) complexes with different counter ions: 
nitrate (blue) (1), perchlorate (green) (2), tetrafluoroborate (red) (3), hexafluoroantimonate (ma-
genta) (4). The best fit for C1, C2 and N1 atoms. 
Taking into account the configuration of the asymmetric atom C1, pairs of micona-
zole ligands within the cation molecule are designated as RR and SS for complexes 1–3, 
which crystallize in the C2/c space group, whereas they are RS in the case of 4 due to the 
silver ion occupying the inversion center. 
In complex 1, the NO3− anion binds strongly to the metal center, in contrast to the 
ClO4−, BF4− and SbF6− counter ions. In the new structures of 3 and 4, there are no close 
AgF contacts. 
Fluorine-containing anions do not participate in the coordination sphere of the 
Ag(I) ion, but both are involved in hydrogen bonds as acceptors. The geometrical details 
of the hydrogen bonds are summarized in Table 3. As shown in Figure 4a, the C3-H3-F1 
hydrogen bond is observed between the cation and anion, whereas the C5-H5Cl1 in-
teraction links the cation molecules into a 1D-chain motif running parallel to the [010] 
direction. The crystal structure of complex 4 is dominated by three weak intermolecular 
C-HF interactions (Figure 4b), which contribute to the formation of the molecular 
ab-layers. The packing diagrams are presented in Figure 5. Close inspection of the crystal 
packing reveals that in both analyzed structures, the aromatic ππ interactions can be 
found between the dichlorophenyl rings C13-C18 of the adjacent chain motifs in 3 and 
between neighboring layers in 4. The centroid-to-centroid distances are 3.720(4)Å  and 
4.095(2)Å ; the perpendicular distances from the centroid to the plane of the opposite ring 
are 3.472(2)Å  and 3.665(2)Å  for 3 and 4, respectively. 
Table 3. Hydrogen bonding geometry (Å , °) for silver(I) complexes 3 and 4. 
H-Bond D–H HA DA D–HA 
3     
C3–H3F1 0.93 2.53 3.292(7) 140 
C5–H5Cl1ii 0.93 2.80 3.434(5) 126 
4     
C2–H2AF1iii 0.97 2.37 3.313(4) 163 
C3–H3F1 0.93 2.35 3.221(4) 156 
C4–H4F3iv 0.93 2.61 3.478(4) 156 
Symmetry codes: 3 (ii) −x, y−1, z; 4 (iii) −x + 1, −y + 1, −z + 1; (iv) x−1, y, z. 






Figure 4. Hydrogen-bonding scheme in 3 (a) and 4 (b). In both cases, hydrogen atoms not involved in H-bonds are 
omitted for clarity. Symmetry codes: 3 (i) −x, y, −z + ½ ; (ii) −x, y−1, z; (iii) −x, y + 1, z; 4 (i) −x + 1, −y + 2, −z + 1; (iii) −x + 1, −y 




Figure 5. The crystal packing of 3 (a) and 4 (b) viewed along the crystallographic b axis. 
2.7. Antimicrobial Activity 
The antimicrobial activity of silver(I) complexes of miconazole, free ligand, silver 
sulfadiazine and the corresponding silver salts was tested against six strains of 
Gram-positive bacteria (Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis 
ATCC 12228, Micrococcus luteus ATCC 10240, Bacillus subtilis ATCC 6633, Bacillus cereus 
ATCC 10876, Enterococcus faecalis ATCC 29212), five strains of Gram-negative bacteria 
(Salmonella typhimurium ATCC 14028, Escherichia coli ATCC 25922, Proteus mirabilis ATCC 
12453, Klebsiella pneumoniae ATCC 13883, Pseudomonas aeruginosa ATCC 9027) and yeasts 
(Candida glabrata ATCC 90030, Candida albicans ATCC 102231, Candida parapsilosis ATCC 
22019). Antimicrobial properties are expressed as MIC (minimum inhibitory concentra-
tion) and MBC/MFC (minimum bactericidal/fungicidal concentration) in μmol/L (Table 
4). The antimicrobial activity of compounds 1–4 was compared with that of the antimi-
crobial and antifungal properties of the corresponding silver salts, miconazole and silver 
sulfadiazine. 
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Table 4. Antimicrobial activity defined as minimal inhibitory concentration (MIC) and minimal bactericidal/fungicidal concentration (MBC/MFC) of silver(I) 
complexes, silver salts and reference compounds—miconazole (MCZ) and silver-sulfadiazine (AgSD). 
Microorganism 
Ag(MCZ)2NO3 AgNO3 Ag(MCZ)2ClO4 AgClO4 Ag(MCZ)2BF4 AgBF4 
(μmol/L) (μmol/L) (μmol/L) (μmol/L) (μmol/L) (μmol/L) 
Gram-positive bacteria MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
S. aureus ATCC 25923 1.95 15.57 22.81 45.61 3.76 30.15 18.84 37.68 1.90 30.51 20.10 80.41 
S. epidermidis ATCC 12228 1.95 15.57 5.73 11.40 3.76 30.15 9.42 75.36 1.90 30.51 5.05 40.21 
M. luteus ATCC 10240 0.49 15.57 11.40 22.81 1.88 7.51 18.84 75.36 0.96 7.60 10.05 80.41 
B. subtilis ATCC 6633 3.89 7.78 22.81 45.61 7.51 15.03 18.84 75.36 7.60 30.51 20.10 40.21 
B. cereus ATCC 10876 7.78 15.57 91.23 91.23 15.03 60.21 37.68 151.21 15.20 30.51 80.41 80.41 
E. faecalis ATCC 29212 15.57 31.24 45.61 91.23 30.15 120.42 37.68 151.21 30.51 60.92 40.21 80.41 
Gram-negative bacteria MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
S. Typhimurium ATCC 14028 62.38 62.38 22.81 91.23 120.42 120.42 18.84 37.68 121.83 243.66 20.10 40.21 
E. coli ATCC 25922 31.24 31.24 45.61 45.61 60.21 60.21 75.36 75.36 121.83 121.83 80.41 80.41 
P. mirabilis ATCC 12453 62.38 62.38 91.23 91.23 60.21 60.21 151.21 151.21 121.83 121.83 80.41 80.41 
K. pneumoniae ATCC 13883 62.38 62.38 45.61 45.61 120.42 120.42 37.68 75.36 121.83 121.83 40.21 40.21 
P. aeruginosa ATCC 9027 31.24 62.38 45.61 45.61 120.42 120.42 37.68 151.21 60.92 121.83 40.21 40.21 
Yeasts MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC MIC MFC 
C. glabrata ATCC 90030 1.95 7.78 11.40 22.81 1.88 30.15 9.42 37.68 1.90 15.20 10.05 20.10 
C. albicans ATCC 102231 0.98 1.95 11.40 91.23 1.88 3.76 9.42 75.36 1.90 3.80 20.10 80.41 
C. parapsilosis ATCC 22019 0.12 0.49 11.40 91.23 0.12 1.88 4.73 75.36 0.12 1.90 10.05 80.41 
Microorganism 
Ag(MCZ)2SbF6 AgSbF6 MCZ AgSD     
(μmol/L) (μmol/L) (μmol/L) (μmol/L)     
Gram-positive bacteria MIC MBC MIC MBC MIC MBC MIC MBC     
S. aureus ATCC 25923 3.32 26.64 22.74 45.48 1.18 9.38 21.85 43.70     
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S. epidermidis ATCC 12228 3.32 26.64 5.69 22.74 1.18 9.38 43.70 43.70     
M. luteus ATCC 10240 1.66 6.64 11.37 45.48 1.18 1.18 10.92 87.68     
B. subtilis ATCC 6633 13.28 26.64 22.74 22.74 4.69 4.69 10.92 21.85     
B. cereus ATCC 10876 13.28 53.19 91.25 182.22 4.69 4.69 43.70 350.14     
E. faecalis ATCC 29212 26.64 106.38 45.48 91.25 9.38 18.75 87.68 87.68     
Gram-negative bacteria MIC MBC MIC MBC MIC MBC MIC MBC     
S. Typhimurium ATCC 14028 212.77 212.77 22.74 45.48 >1000 Nd 43.70 87.68     
E. coli ATCC 25922 212.77 212.77 91.25 91.25 >1000 Nd 43.70 87.68     
P. mirabilis ATCC 12453 212.77 212.77 91.25 91.25 >1000 Nd 21.85 43.70     
K. pneumoniae ATCC 13883 212.77 212.77 45.48 45.48 >1000 Nd 43.70 87.68     
P. aeruginosa ATCC 9027 106.38 106.38 45.48 45.48 >1000 Nd 21.85 43.70     
Yeasts MIC MFC MIC MFC MIC MFC MIC MFC     
C. glabrata ATCC 90030 0.83 13.28 11.37 22.74 4.69 18.75 10.92 43.70     
C. albicans ATCC 102231 1.66 3.32 11.37 91.25 4.69 9.38 10.92 43.70     
C. parapsilosis ATCC 22019 0.10 0.83 11.37 91.25 0.07 1.18 5.46 43.70     
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All silver(I) complexes showed significantly higher activity against Gram-positive 
bacteria than that of silver sulfadiazine and silver salts. Their MIC activity was up to 
23-fold higher than that of AgSD and the corresponding silver salts. They inhibited the 
growth of all Gram-positive bacteria at low concentrations. The most sensitive bacteria to 
the tested compounds 1–4 were staphylococci and micrococcus. It was shown that the 
synthesized compounds inhibited the growth of the M. luteus bacterial strain at concen-
trations of 0.49 μmol/L (for compound 1) to 1.88 μmol/L (for compound 2). The most ac-
tive complex against this bacterium was complex 1, which inhibited the growth of M. 
luteus at a 23-fold lower concentration than that of AgNO3 and 22-fold lower concentra-
tion than that of silver sulfadiazine. Other complexes showed 6- or 11-fold higher activity 
than that of silver sulfadiazine. 
The tested complexes also revealed good antimicrobial activity against 
Gram-negative bacteria, but it was weaker than that against Gram-positive bacteria. 
Out of the Gram-negative rods, the most sensitive was P. aeruginosa, the growth of 
which was inhibited most intensively by compounds 1, 3 and 4 at concentrations of 31.24, 
60.92 and 106.38 μmol/L, respectively. On the other hand, the activity of E. coli was best 
inhibited by compounds 1 and 2 at concentrations of 31.24 and 60.21 μmol/L. The MIC 
values of all complexes were slightly higher than those of the corresponding silver and 
sulfadiazine salts. The only exception was compound 1, which showed better activity 
against E. coli than AgNO3 and silver sulfadiazine. 
Moreover, the synthesized silver(I) complexes of miconazole were very active 
against yeasts. Even at low concentrations of 0.10–0.12 μmol/L, they inhibited the growth 
of C. parapsilosis, and at concentrations ranging from 0.83 to 1.95 μmol/L, they decreased 
the growth of C. glabrata and C. albicans. The corresponding silver salts and AgSD had 
significantly lower activity than that of complex compounds for all tested yeasts. 
The MBC values for the tested complexes also confirmed that their activity against 
Gram-positive bacteria and yeasts was higher than that against Gram-negative bacteria 
in comparison to silver salts and silver sulfadiazine. The low values of the MBC/MIC ra-
tio for complexes (1–4) suggested their bactericidal power against Gram-negative rods 
and Gram-positive bacilli in contrast to the higher values (8–16) for these complexes in-
dicating bacteriostatic activities against staphylococci. A fungicidal effect (MFC/MIC ≤ 4) 
was found for Ag(MCZ)2NO3. The remaining complexes revealed fungistatic activity 
against the tested yeasts (MFC/MIC > 4), except for C. albicans. 
The results for miconazole showed that its activity against Gram-positive bacteria 
was higher than that of the tested complexes. In contrast, the free ligand showed no in-
hibition of the growth of Gram-negative bacteria when it was below 1000 μmol/L, in 
contrast to all synthesized silver(I) complexes, which had moderate activity against these 
bacteria. Importantly, compared to the free drug, all of the complexes had 2-fold higher 
activity in relation to yeasts of C. glabrata and C. albicans and equal activity against C. 
parapsilosis.  
In summary, the tested complexes were more effective than salts and silver sul-
fadiazine against selected Gram-positive and yeast pathogens. In addition, the best an-
timicrobial properties were shown by complex 1, which could potentially be used to treat 
serious skin infections, wounds and burns caused by the tested bacterial strains and 
yeasts as an alternative to the popularly used AgSD. Previous studies have indicated that 
antimicrobial activity increases with decreasing molecular weight of the compound [59]. 
Compound 1, containing the NO3- anion, has the lowest molecular weight among the 
silver(I) complexes presented in our work. It also seems interesting that the structure of 
this compound significantly differs from the other structures of Ag(I) complexes with 
miconazole, primarily in the connection of the nitrate ion with the silver(I) ion. In com-
plex 1, the NO3- anion strongly binds to the metal center, in contrast to the counter ions 
BF4-, ClO4- and SbF6- counter ions. It has also been shown that silver(I) complexes with 
other drugs, e.g., naproxen, have strong antimicrobial properties and may be good can-
didates as antibacterial agents [60]. The studied silver(I) complexes of miconazole are 
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much less active against Gram-negative bacteria than against Gram-positive bacteria. 
Similarly, previous studies have shown that the miconazole complexes of different met-
als are inactive against the Gram-negative bacteria E. coli, P. aeruginosa and Yersinia 
pseudotuberculosis, while they are effective against various strains of Gram-positive bac-
teria [59,61]. The different activity of silver(I) complexes against Gram-positive and 
Gram-negative bacteria may be caused by the difference in the structure of the cell walls 
of these bacteria and their interaction with the tested compounds (1–4). In the case of 
Gram-positive bacteria, their wall is made of peptidoglycan, while Gram-negative bacte-
ria have an additional outer layer that contains a liposaccharide. 
Previous studies have also indicated that different imidazole derivatives have good 
antimicrobial properties. The authors reported a good antibacterial effect of metronida-
zole silver(I) complexes against S. epidermidis, S. aureus, P. aeruginosa and E. coli [23]. The 
results of the research indicate that [Ag(MTZ)2NO3], [Ag(MTZ)2ClO4] and [Ag(MTZ)2BF4] 
compounds have significantly weaker activity in relation to S. epidermidis and S. aureus 
than that of the [Ag(MCZ)2NO3], [Ag(MCZ)2ClO4] and [Ag(MCZ)2BF4] compounds de-
scribed in our article. S. aureus growth inhibition by silver(I) complexes of miconazole 
was 25-fold higher than that by silver(I) complexes of metronidazole. On the other hand, 
the antibacterial activity of compounds 1–3 against S. epidermidis was 10-fold better than 
that of compounds with metronidazole. The above comparison shows that the appropri-
ate choice of the free ligand may lead to better antimicrobial properties. 
3. Experimental Section 
3.1. Chemicals and Reagents 
Analytical standards of silver tetrafluoroborate (CAS:14104-20-2; molecular weight: 
194 g/mol), silver hexafluoroantimonate (CAS: 26042-64-8; molecular weight: 343 g/mol) 
and silver sulfadiazine (CAS: 22199-08-2; molecular weight: 357 g/mol) were purchased 
from Sigma Aldrich (Poznań, Poland). Miconazole (CAS: 22946-47-8; molecular weight 
416 g/mol) was purchased from Alfa Aesar (Kandel, Germany). All other chemicals were 
purchased from commercial suppliers and were of the highest available purity. 
3.2. Synthesis  
3.2.1. Synthesis of [Ag(Miconazole)2BF4] (3) 
AgBF4 (0.5 mmol, 0.100 g) was dissolved in 5 mL of distilled water and was added to 
a miconazole (MCZ) ethanolic solution (miconazole (1 mmol, 0.416 g) in 10 mL of etha-
nol). The mixture was stirred for 24 h at room temperature. The precipitate was filtered 
off and washed in portions of diethyl ether. Crystals suitable for X-ray diffraction were 
obtained by diffusion in a tube with an aqueous solution of AgBF4 (0.1 mmol, 3 mL) at the 
bottom, methanol (2 mL) in the middle and a methanol solution of miconazole (0.2 mmol, 
2 mL) on the top. M.w. 1026.87 g/mol; yield: (0.42 g, 82%); M.p. 161–164 °C. ESI-MS 
(methanol) m/z: 938.87 [Ag(MCZ)2]+. El. anal. Measured (calc.%): C—42.17 (42.11); 
H—2.46 (2.74); N—5.47 (5.47). 1H NMR (600 MHz, CDCl3) δ (ppm): 4.18 (m, 4H, 2 × 
N—CH2), 4.20 (m, 2H, 2 × CH—O), 4.56 (s, 4H, 2 × CH2—O), 7.07 (s, 2H, 2 × CH═C), 7.29 
(s, 2H, 2 × CH═C), 7.33 (m, 2H, 2 × CH—N), 7.34 (m, 2H, 2 × CH—N), 7.35 (m, 2H, 2 × 
CH═C), 7.39 (s, 2H, 2 × CH═C), 7.41 (s, 2H, 2 × CH═C), 7.49 (d, 2H, 2 × CH═C, J = 1.90 
Hz), 8.17 (s, 2H, 2 × CH—N). 13C NMR (600 MHz, CDCl3) δ (ppm): 140.40 (N═C—N), 
134.61 (C—CH), 134.40 (C—Cl), 134.31 (C—Cl), 133.72 (C═CH), 133.67 (C—Cl), 131.38 
(C—Cl), 129.82 (CH═C), 129.56 (CH—CH), 129.56 (CH═C), 129.30 (CH═C), 129.14 
(CH—CH), 128.42 (CH—CH), 127.89 (CH═CH), 121.50 (CH—N), 76.95 (CH—O), 67.85 
(CH2—O), 50.97 (CH2—N). IR (KBr) νmax/cm−1: 3129, 3094, 2975 (C—H) 1728 (C═N), 1590, 
1562 (C—C, C═C), 1526 (C—C, C—H, C═C), 1471 (C—H, C═C), 1438 (C═C), 1248, 1139, 
1120, 1094 (C—O—C), 1071 (BF4), 849, 815 (C—Cl).  
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3.2.2. Synthesis of [Ag(Miconazole)2SbF6] (4) 
To an ethanolic solution of miconazole (1 mmol, 0.416 g, in 10 mL of ethanol) was 
added dropwise an aqueous AgSbF6 solution (0.5 mmol, 0.172 g in 5 mL in water). The 
mixture was stirred on a magnetic stirrer for 24 h at room temperature. The product was 
filtered off and washed in diethyl ether. Colorless crystals suitable for X-ray diffraction 
were grown in pure acetonitrile at room temperature. M.w. 1175.77 g/mol; yield: (0.38 g, 
65%); M.p. 157–161 °C. ESI-MS (methanol) m/z: 938.87 [Ag(MCZ)2]+. El. anal. Measured 
(calc.%): C—36.76 (36.78); H—2.11 (2.39); N—4.76 (4.77). 1H NMR (600 MHz, CDCl3) 
δ (ppm): 4.17 (m, 4H, 2 × N—CH2), 4.20 (m, 2H, 2 × CH—O), 4.56 (s, 4H, 2 × CH2—O), 
7.05 (s, 2H, 2 × CH═C), 7.29 (s, 2H, 2 × CH═C), 7.33 (m, 2H, 2 × CH—N), 7.34 (m, 2H, 2 × 
CH—N), 7.36 (m, 2H, 2 × CH═C), 7.41 (s, 2H, 2 × CH═C), 7.42 (s, 2H, 2 × CH═C), 7.49 (d, 
2H, 2 × CH═C, J = 1.90 Hz), 8.13 (s, 2H, 2 × CH—N). 13C NMR (600 MHz, CDCl3) δ (ppm): 
140.41 (N═C—N), 134.61 (C—CH), 134.39 (C—Cl), 134.31 (C—Cl), 133.72 (C═CH), 133.67 
(C—Cl), 131.38 (C—Cl), 129.81 (CH═C), 129.57 (CH—CH), 129.57 (CH═C), 129.30 
(CH═C), 129.15 (CH—CH), 128.42 (CH—CH), 127.89 (CH═CH), 121.49 (CH—N), 76.95 
(CH—O), 67.85 (CH2—O), 50.97 (CH2—N). IR (KBr) νmax/cm−1:3180, 3137, 3061, 2957 
(C—H) 1729 (C═N), 1590, 1562 (C—C, C═C), 1526 (C—C, C—H, C═C), 1470 (C—H, 
C═C), 1437 (C═C), 1248, 1139, 1119, 1095 (C—O—C), 848, 819 (C—Cl), 658 (SbF6). 
3.3. Light Stability 
The light stability of the compounds (1–4) was studied in normal light at room 
temperature. Silver(I) complexes of miconazole and their corresponding silver salts were 
dissolved in water to a volume of 2.5 µmol (50 µL) and then applied to impregnate var-
ious substrates: tissue paper, paper and glass. The concentration of each solution was 
0.05 M.  
The stability of all compounds was monitored visually for 108 h, and photographs 
were acquired after 0, 1, 4, 18, 24, 40, 48, 52, 60, 84 and 108 h. The photos are shown in 
Supplementary Figure S4. 
3.4. X-Ray Single-Crystal Diffraction 
The single-crystal X-ray diffraction experiments for silver(I) complexes 3 and 4 were 
carried out using a SuperNova diffractometer equipped with a microfocus X-ray tube, 
optimized multi-layer optics for MoKα (λ = 0.71073Å ) radiation and an Atlas CCD de-
tector. Measurements were carried out at room temperature. Control of the measure-
ment procedure and data reduction were performed by CrysAlisPro software (version 
1.171.38.41q; Rigaku Oxford Diffraction, 2015); the same program was used to determine 
and refine the lattice parameters. For integration of the collected data and correction of 
Lorentzian and polarization effects, the CrysAlis RED program was used (version 
1.171.38.41q; Rigaku Oxford Diffraction, 2015) [62]. The structures were solved with 
SHELXT [63] and refined with SHELXL-2018/3 [64]. Hydrogen atoms were placed in 
idealized positions and refined as riding atoms. Experimental details, as well as a sum-
mary of the crystallographic data and structure refinement, are given in Table 5.  
In structure 3, the Cl2 and F2 atoms were found to be disordered. The final occupa-
tion factors kA:kB were refined to 0.60(5): 0.40(5) for the Cl2 atom and 0.553(13): 
0.447(13) for the F2 atom, respectively. The ellipsoids of the A and B components were 
modeled. Bond-length restraints were applied to all C-Cl (C9-Cl2A, C9-Cl2B) and B-F 
(B1-F1, B1-F2A, B1-F2B) bonds involving the disordered atoms. 
Additionally, a high residual-density peak around atom H18 was revealed during 
the refinement of 3. Given the disorder of the chlorine Cl3 atom over two related ortho 
positions in the phenyl ring, two sets of split sites were used for the following atoms: 
Cl3B/Cl3A and H14/H18. The site-occupation factors are 0.845(5) for Cl3A/H18 and 
0.155(5) for Cl3B/H14. The distances between atom pairs C14-Cl3A and C18-Cl3B were 
restrained to be equal.  
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Table 5. Crystallographic data for 3 and 4. 
 3 4 
Empirical formula C36H28AgCl8N4O2·BF4 C36H28AgCl8N4O2·SbF6 
Formula weight 1026.90 1175.84 
Crystal system Monoclinic Triclinic 
Space group C2/c P1̅ 
a (Å ) 15.6809(10) 8.3845(6) 
b (Å ) 8.5678(5) 8.8813(5) 
c (Å ) 30.601(2) 14.9005(11) 
α (°) 90.000 91.261(5) 
β (°) 96.353(5) 93.497(5) 
γ (°) 90.000 110.570(5) 
V (Å 3) 4086.0(5) 1035.77(12) 
Z 4 1 
T (K) 293(1) 293(1) 
F (000) 2048 576 
Dx (g∙cm−3) 1.669 1.885 
µ (mm−1) 1.074 1.71 
Wavelength (Å ) 0.71073 0.71073 
θ range (°) 3.1–27.0 3.2–30.0 
Measured reflections 17115 11524 
Unique reflections 4455 6013 
Observed reflections [I > 2σ (I)] 2961 4135 
Completeness to θmax (%) 99.8 99.4 
Parameters/restraints 284/47 265/0 
R [F2 > 2σ (F2)] 0.065 0.040 
wR (all data) 0.196 0.101 
S 1.06 1.01 
The graphical material for structural studies was generated with the Mercury pro-
gram [65]. Supplementary crystallographic data for this paper can be found at the Cam-
bridge Crystallographic Data Center under the depository numbers CCDC 2054546 (3) 
and 2054547 (4). 
3.5. Chemistry 
The melting points of all silver(I) complexes of miconazole were determined with a 
Böetius apparatus. Elemental analysis (C, H, N) was performed using the Perkin Elmer 
2400 Series II Analyzer (PerkinElmer, Waltham, MA, USA). Electrospray ionization mass 
spectra (ESI-MS) were registered on a Varian 500-MS LC Trap (Varian Inc., Palo Alto, CA, 
USA). Infrared spectra were recorded in the range 4000–400 cm−1 on a Bruker Alpha-T 
spectrophotometer (Bruker Corporation, Billerica, MA, USA) using KBr pellets. 1H and 
13C NMR spectra were collected with a Bruker advance III 600 MHz spectrophotometer 
(Bruker Corporation, Billerica, MA, USA) using CDCl3 as a solvent. 
3.6. Antibacterial Activity Studies 
All tested compounds were screened for antibacterial and antifungal activities using 
a micro-dilution broth method according to the European Committee on Antimicrobial 
Susceptibility Testing—EUCAST (www.eucast.org) using Mueller–Hinton broth and 
RPMI 1640 (Roswell Park Memorial Institute Medium) supplemented with 2% glucose 
and MOPS (3-(N-morpholino) propanesulfonic acid) for the growth of bacteria and fungi, 
respectively. The minimal inhibitory concentration (MIC) and minimal bactericid-
al/fungicidal concentration (MBC/MFC) of the tested complexes were evaluated for the 
panel of the reference microorganisms from American Type Culture Collection (ATCC), 
including Gram-negative bacteria (Escherichia coli ATCC 25922, Salmonella Typhimurium 
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ATCC14028, Klebsiella pneumoniae ATCC 13883, Pseudomonas aeruginosa ATCC 9027, Pro-
teus mirabilis ATCC 12453), Gram-positive bacteria (Staphylococcus aureus ATCC 25923, 
Staphylococcus epidermidis ATCC 12228, Micrococcus luteus ATCC 10240, Enterococcus fae-
calis ATCC 29212, Bacillus subtilis ATCC 6633, Bacillus cereus ATCC 10876) and fungi 
(Candida albicans ATCC 10231, Candida parapsilosis ATCC 22019, Candida glabrata ATCC 
90030). The antimicrobial assays were performed in the same manner as in our previous 
research [66]. Each experiment was repeated in triplicate. Representative data are pre-
sented. 
4. Conclusions 
In this article, we present the continuation of biological research on the previously 
obtained complex compounds Ag(MCZ)2NO3 and Ag(MCZ)2ClO4, as well as propose the 
synthesis of two new silver complex compounds containing tetrafluoroborate and hex-
afluoroantimonate counter ions with the biologically active ligand miconazole. Their 
method of synthesis is simple and reproducible, which, combined with the promising 
results, shows great potential for their practical application in the treatment of bacterial 
and fungal infections. Their antibacterial and antifungal activities against six 
Gram-positive bacteria, five Gram-negative strains and fungi were assessed in compari-
son with the drug silver sulfadiazine, the ligand and the corresponding silver salts. 
In our work, all synthesized silver(I) complexes (1–4) show much better activity in 
inhibiting the growth of Gram-positive bacteria and yeasts in comparison to silver sul-
fadiazine and silver salts. Moreover, against Gram-negative bacteria, their activity is 
better than that of miconazole. Furthermore, we can conclude that our compounds may 
be a better alternative to miconazole against yeast infections, including C. albicans. 
Our study also shows that the presence of certain counter ions influences antimi-
crobial activity. The Ag(I) complex containing the nitrate counter ion is best at inhibiting 
the growth of Gram-positive and Gram-negative bacteria and yeasts. 
Considering the problem of increasing drug resistance to popular antibiotics and 
drugs, all of our synthesized silver(I) complexes have great potential and can be good 
candidates for combating infections caused by bacteria and fungi. 
Supplementary Materials: Supplementary Materials can be found at 
www.mdpi.com/1422-0067/22/4/1510/s1. 
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